Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28780251 | 1.00 | CCR2 (0.50) | CCR2CCR5KCNH2PANK3AKR1C3 | |
| SCHEMBL1777401 | 0.87 | CCR2 (0.55) | CCR2CCR5KCNH2PANK3HRH3 | |
| SCHEMBL27741688 | 0.87 | CCR2 (0.55) | CCR2CCR5KCNH2PANK3HRH3 | |
| SCHEMBL1777729 | 0.85 | HRH3 (0.59) | PANK3HRH3 | |
| SCHEMBL4650459 | 0.85 | HRH3 (0.59) | PANK3HRH3 | |
| SCHEMBL1778248 | 0.84 | KDM4E (0.54) | CCR2CCR5KCNH2PANK3HRH3 | |
| SCHEMBL27762255 | 0.84 | CCR2 (0.47) | CCR2CCR5KCNH2HRH3 | |
| SCHEMBL1777190 | 0.84 | CCR2 (0.47) | CCR2CCR5KCNH2HRH3 | |
| SCHEMBL4692908 | 0.82 | HRH3 (0.55) | PANK3HRH3 | |
| SCHEMBL1777343 | 0.78 | CCR2 (0.55) | CCR2CCR5KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2007071952-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | CCR2, CCR5, CCL2 | CCR2 1/4885CCR5 2/4885KCNH2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.